KZIA News
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).read more...
Benzinga
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).read more...
Benzinga
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation ConferencePR NewswireSYDNEY, Oct. 29, 2026 SYDNEY, Oct. 29, 2026 /PRNewswire/ -- Kazia...
PR Newswire
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersPR NewswireSYDNEY, Sept. 22, 2026 Clinical Milestone...
PR Newswire
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer PR Newswire SYDNEY...
PR Newswire
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances...
PR Newswire
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing...
PR Newswire
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 31, 2026 Company to host a corporate update call Tuesday, September 1st at...
PR Newswire
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 28, 2026 SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the...
PR Newswire
Kazia Therapeutics Limited Announces Proposed Public Offering
Kazia Therapeutics Limited Announces Proposed Public Offering Kazia Therapeutics Limited Announces Proposed Public Offering PR Newswire SYDNEY, Aug. 27, 2026 SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology...
PR Newswire
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer PR Newswire SYDNEY, Aug. 27, 2026 Durable...
PR Newswire